SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)
Website: www.sinobiopharm.com
(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
COMPLETION OF PATIENT ENROLLMENT IN PHASE III CLINICAL TRIAL OF ANLOTINIB (A CATEGORY I INNOVATIVE DRUG) COMBINED WITH CHEMOTHERAPY IN FIRST-LINE TREATMENT OF ADVANCED SOFT TISSUE SARCOMA

The board of directors (the "**Board**") of Sino Biopharmaceutical Limited (the "**Company**", together with its subsidiaries, the "**Group**") announces that the Group is conducting a "Multicenter, Randomized, Double-blind, Parallel-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Capsules combined with Epirubicin Hydrochloride for Injection Versus Placebo Combined with Epirubicin Hydrochloride for Injection in the First-Line Treatment of Advanced Soft Tissue Sarcoma", which has recently successfully completed patient enrollment.

Soft Tissue Sarcoma ("**STS**") is highly heterogeneous tumour characterized by local aggressiveness, infiltrative or destructive growth, local recurrence and distant metastasis, with 19 tissue types and more than 50 different subtypes, and can occur anywhere in the body. The incidence of STS ranges from 1.28/100,000 to 172/100,000, and it can occur at any age, with a slightly higher incidence rate in males than in females. For unresectable locally advanced or metastatic STS, palliative chemotherapy with anthracycline-based drugs is recommended for the first-line treatment of locally advanced or metastatic STS, although the sensitivity of different sarcoma subtypes to chemotherapeutic agents varies.

Anlotinib Hydrochloride Capsules is a multi-targeted receptor tyrosine kinase inhibitor developed by the Group. It received clinical study approval from the National Medical Products Administration in March 2011 and was approved for marketing in May 2018 for patients with previously treated advanced non-small-cell lung cancer, and has since been approved for the indications of STS, small-cell lung cancer, medullary thyroid cancer and differentiated thyroid cancer. Its indication for the first-line treatment of small cell lung cancer in combination with Benmelstobart (anti-PD-L1) and chemotherapy is under technical review by the Center for Drug Evaluation of the National Medical Products Administration ("**CDE**").

The results of an early exploratory study of first-line treatment of advanced STS with Anlotinib in combination with Epirubicin sequential Anlotinib have been published in Clinical Cancer Research, which showed that the combination treatment had an objective response rate ("**ORR**") of 13.3%, a disease control rate ("**DCR**") of 80%, a median progression-free survival rate ("**mPFS**") of 11.5 months, and was safe and tolerable. The Phase III clinical trial of Anlotinib in combination with Epirubicin for the first-line treatment of advanced STS has successfully completed the patient enrollment, marking a critical step in the marketing process of Anlotinib from the backline into the first-line in STS indications, and also implying that the combination of Anlotinib with chemotherapy is expected to bring a brand-new therapeutic option for first-line STS patients.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 22 December 2023

As at the date of this announcement, the Board of the Company comprises seven executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.